Võtame sihikule harvikhaigused
AOP Health on Euroopas teerajaja harvikhaigustega (mida tuntakse ka orbhaigustena) inimestele mõeldud ravimite väljatöötamisel, tootmisel ja turustamisel.
Team
„On privileeg rakendada oma farmaatsia- ja ärindusalast haridust ning rohkem kui 25-aastast professionaalset kogemust, parandamaks harvikhaigustega inimeste elusid Eestis. Oleme siin tegutsenud alates 2009. aastast ning jätkame uuenduslike ja tõhusate ravilahenduste pakkumist!"
Faktid ja joonised
AOP Health on pühendunud farmaatsia- ja kliinilisele arendusele ning ravimite turustamisele juba üle 20 aasta.
Meie motivatsioon AOP Health'is on aidata harvikhaigusi põdevaid patsiente. Me saavutame selle koostöö Eesti tervishoiusüsteemi huvigruppidega. Farmaatsia- ja tervishoiutööstuse partnerlused on patsientide lahenduste leidmisel ja pakkumisel üliolulised, eriti harvikhaiguste ravis.
Eestil on eriline positsioon paljude riikide seas, kus AOP Health esindatud on. Sellel turul alustas ettevõte oma arendustegevust 2009. aastal koos kohaliku turunduse, müügi ning meditsiini valdkonna meeskonnaga kõigis kolmes terapeutilises rühmas.
History of more than 20 years means many significant milestones — in research, social, business spheres and regulatory affairs — that were and are important for AOP Health.
Foundation of AOP Health in Vienna
The Orphan Regulation EC no 141/2000
1st Approval of Anagrelide in Europe
European Union Expansion
Prostacyclin Analogues Approval
JAK2 Discovery
Renaissance of Interferon (IFNα)
UDCA Designation
Tetrabenazine Approval in Central Europe
Nabilone Approval in Austria
Start of the PROUD PV Study
Beta-blocker for severe sepsis
Pitolisant approval
Landiolol approval
Treprostinil and PAH
BESREMi® Approval
Corporate culture
Since its very start AOP Health has borne the social responsibility of further life quality improvement for patients with severe, rare and life-threatening diseases. We at AOP Health conduct intensive research for this purpose, believing that developing and providing solutions for patients is the most important part of the AOP Health corporate responsibility. When it comes to wanting the best for the patients, we stand side-by-side with each other as a team, with researches, physicians, therapists, caregivers, patient organizations and other stakeholders.
AOP Health is keen to keep one of its greatest assets – it is closely networked with the key specialists in all markets and is therefore able to help patients with rare diseases from Austria throughout the world.
From its inception AOP Health's culture is shaped by the entrepreneurial spirit of its founder. We are proud to be a company that encourages employees to come up with new ideas and to show ownership and initiative every day. To help neglected patients with rare diseases is our key motivator. Through close interaction with the scientific community, care givers and partners we aim to provide therapies and help patients beyond just providing drugs.
The future
Thanks to our advancements in the field of therapies, an increasing number of patients survive their disease or are able to live with it for a longer period of time. In the next few decades, personalized medicine, individual treatment opportunities will emerge more and more as the standard in AOP Health’s therapy concepts as well.
Novel technologies such as next-generation sequencing (NGS) will play an equally crucial role as the increasing quantities of big data and conclusions derived from the daily lives of patients also beyond the strictly regulated conditions of clinical trials, e.g. real-world evidence.
Furthermore, the increasing health competence, health literacy of patients and their family members will also determine the future of pharma and health care sector.